$SUPN
SUPERNUS PHARMACEUTICALS, INC. Stock $supn

$supn Overview Financials Valuation SEC Filings Company Website

2020 Form 10-K Financial Statement

#000135657621000028 Filed on March 08, 2021

Income Statement

Concept	2020	2019 Q4	2019
Revenue	$520.4M	$100.4M	$392.8M
YoY Change	32.5%	-13.36%	-3.95%
Cost Of Revenue	$52.46M	$4.100M	$16.66M
YoY Change	214.88%	-2.38%	8.49%
Gross Profit	$467.9M	$96.30M	$376.1M
YoY Change	24.42%	-13.79%	-4.43%
Gross Profit Margin	89.92%	95.87%	95.76%
Selling, General & Admin	$200.7M	$35.70M	$153.2M
YoY Change	30.95%	-15.2%	-0.94%
% of Gross Profit	42.89%	37.07%	40.75%
Research & Development	$75.96M	$19.80M	$69.10M
YoY Change	9.93%	-33.56%	-22.54%
% of Gross Profit	16.23%	20.56%	18.37%
Depreciation & Amortization	$18.14M	$1.700M	$6.659M
YoY Change	172.43%	0.0%	-5.72%
% of Gross Profit	3.88%	1.77%	1.77%
Operating Expenses	$276.6M	$55.50M	$222.3M
YoY Change	24.42%	-22.81%	-8.84%
Operating Profit	$173.7M	$40.82M	$148.6M
YoY Change	16.91%	2.41%	2.86%
Interest Expense	$19.44M	-$3.300M	$18.21M
YoY Change	6.74%	-3400.0%	31.55%
% of Operating Profit	11.19%	-8.09%	12.25%
Other Income/Expense, Net	-$5.050M	$3.400M	-$1.084M
YoY Change	365.87%	-383.33%	-74.6%
Pretax Income	$168.6M	$40.90M	$147.5M
YoY Change	14.35%	5.41%	5.22%
Income Tax	$41.70M	$7.800M	$34.43M
% Of Pretax Income	24.72%	19.07%	23.35%
Net Earnings	$127.0M	$33.13M	$113.1M
YoY Change	12.29%	27.95%	1.86%
Net Earnings / Revenue	24.39%	32.98%	28.79%
Basic Earnings Per Share	$2.41	$0.63	$2.16
Diluted Earnings Per Share	$2.36	$0.62	$2.10
COMMON SHARES
Basic Shares Outstanding	52.62M shares	52.46M shares	52.41M shares
Diluted Shares Outstanding	53.69M shares		53.82M shares

Balance Sheet

Concept	2020	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$422.5M	$347.1M	$347.1M
YoY Change	21.72%	-2.5%	-2.5%
Cash & Equivalents	$288.6M	$181.4M	$181.4M
Short-Term Investments	$133.9M	$165.7M	$165.7M
Other Short-Term Assets	$18.70M	$11.60M	$11.60M
YoY Change	61.21%	30.34%	30.34%
Inventory	$48.30M	$26.63M	$26.60M
Prepaid Expenses
Receivables	$140.9M	$87.33M	$87.30M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$630.4M	$472.6M	$472.6M
YoY Change	33.39%	-4.22%	-4.24%
LONG-TERM ASSETS
Property, Plant & Equipment	$58.10M	$17.07M	$38.30M
YoY Change	51.7%	316.8%	834.15%
Goodwill		$0.00
YoY Change
Intangibles		$24.84M
YoY Change		-20.81%
Long-Term Investments	$350.4M	$591.8M	$591.8M
YoY Change	-40.79%	41.31%	41.31%
Other Assets	$23.00M	$21.89M	$32.70M
YoY Change	-29.66%	5661.58%	8.64%
Total Long-Term Assets	$873.7M	$687.6M	$687.7M
YoY Change	27.05%	41.98%	42.0%
TOTAL ASSETS
Total Short-Term Assets	$630.4M	$472.6M	$472.6M
Total Long-Term Assets	$873.7M	$687.6M	$687.7M
Total Assets	$1.504B	$1.160B	$1.160B
YoY Change	29.63%	18.66%	18.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.100M	$10.14M	$10.10M
YoY Change	-39.6%	217.4%	215.63%
Accrued Expenses	$189.4M	$49.71M	$144.8M
YoY Change	30.8%	36.07%	0.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.800M
YoY Change
Total Short-Term Liabilities	$245.1M	$160.6M	$160.6M
YoY Change	52.62%	-0.47%	-0.5%
LONG-TERM LIABILITIES
Long-Term Debt	$382.0M	$345.2M	$345.2M
YoY Change	10.66%	4.76%	4.76%
Other Long-Term Liabilities	$96.90M	$28.66M	$59.10M
YoY Change	63.96%	151.42%	73.82%
Total Long-Term Liabilities	$478.9M	$28.66M	$404.3M
YoY Change	18.45%	151.42%	11.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$245.1M	$160.6M	$160.6M
Total Long-Term Liabilities	$478.9M	$28.66M	$404.3M
Total Liabilities	$759.2M	$564.9M	$564.9M
YoY Change	34.4%	7.63%	7.64%
SHAREHOLDERS EQUITY
Retained Earnings		$199.5M
YoY Change		130.71%
Common Stock		$53.00K
YoY Change		1.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$744.9M	$595.4M	$595.4M
YoY Change
Total Liabilities & Shareholders Equity	$1.504B	$1.160B	$1.160B
YoY Change	29.63%	18.66%	18.66%

Cashflow Statement

Concept	2020	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	$127.0M	$33.13M	$113.1M
YoY Change	12.29%	27.95%	1.86%
Depreciation, Depletion And Amortization	$18.14M	$1.700M	$6.659M
YoY Change	172.43%	0.0%	-5.72%
Cash From Operating Activities	$138.4M	$43.80M	$143.1M
YoY Change	-3.3%	33.13%	10.96%
INVESTING ACTIVITIES
Capital Expenditures	$3.449M	-$2.000M	$2.736M
YoY Change	26.06%	1900.0%	224.17%
Acquisitions	$298.5M		$0.00
YoY Change
Other Investing Activities	-$31.30M	$21.50M	-$155.2M
YoY Change	-79.83%	-37.68%	-62.38%
Cash From Investing Activities	-$34.70M	$19.50M	-$157.9M
YoY Change	-78.03%	-43.15%	-61.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$4.361M		$3.928M
YoY Change	11.02%		-66.09%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.559M	1.200M	$3.928M
YoY Change	-9.39%	0.0%	-98.96%
NET CHANGE
Cash From Operating Activities	$138.4M	43.80M	$143.1M
Cash From Investing Activities	-$34.70M	19.50M	-$157.9M
Cash From Financing Activities	$3.559M	1.200M	$3.928M
Net Change In Cash	$107.3M	64.50M	-$10.87M
YoY Change	-1087.02%	-5.7%	-111.82%
FREE CASH FLOW
Cash From Operating Activities	$138.4M	$43.80M	$143.1M
Capital Expenditures	$3.449M	-$2.000M	$2.736M
Free Cash Flow	$135.0M	$45.80M	$140.4M
YoY Change	-3.88%	38.79%	9.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001356576
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201609Member
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OperatingLeaseLiabilityNoncurrent
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:PropertyPlantAndEquipmentNet
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2590184
CY2020	dei	Entity File Number EntityFileNumber	001-35518
CY2020	dei	Entity Registrant Name EntityRegistrantName	SUPERNUS PHARMACEUTICALS, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	9715 Key West Avenue
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2020	dei	City Area Code CityAreaCode	(301)
CY2020	dei	Local Phone Number LocalPhoneNumber	838-2500
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.001 Par Value
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	52923107	shares
CY2020	dei	Trading Symbol TradingSymbol	SUPN
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	1205174821	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	288640000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	181381000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	133893000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	165692000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	140877000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	87332000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	48325000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	26628000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18682000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11611000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	630417000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	472644000	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	350359000	USD
CY2019Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	591773000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37824000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17068000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	364342000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24840000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	77911000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	0	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	32063000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	43249000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21894000	USD
CY2020Q4	us-gaap	Assets Assets	1504102000	USD
CY2019Q4	us-gaap	Assets Assets	1160282000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	78934000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	49714000	USD
CY2020Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	126192000	USD
CY2019Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	107629000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	30900000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9082000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3244000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	245108000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	160587000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	361751000	USD
CY2019Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	345170000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	45800000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28579000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30440000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	35215000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	42791000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28657000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	759244000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	564854000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52868482	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52868482	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52533348	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52533348	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	53000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15356000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	53000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	409332000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	388410000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8975000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7417000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	326498000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	199548000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	744858000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	595428000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1504102000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1160282000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	520397000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	392755000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	408897000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	52459000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16660000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	89209000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	75961000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69099000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	200677000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	153246000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	154698000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15702000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5179000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5190000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1900000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	346699000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	244184000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	264453000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	173698000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	148571000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	144444000	USD
CY2020	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	23754000	USD
CY2019	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	22707000	USD
CY2018	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	18111000	USD
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	18704000	USD
CY2019	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	21623000	USD
CY2018	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	13843000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5050000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1084000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4268000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	168648000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	147487000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	140176000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	41698000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34431000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29183000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	113056000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	110993000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.41
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.16
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.13
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.36
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.10
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.05
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52615269	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52412181	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51989824	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53689743	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53816754	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54098872	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	113056000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	110993000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1558000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	10575000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2411000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1558000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	10575000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2411000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	128508000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	123631000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	108582000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	267480000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11291000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11582000	USD
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	56215000	USD
CY2018	supn	Adjustments To Additional Paid In Capital Purchases Of Convertible Note Hedges Net Of Tax AdjustmentsToAdditionalPaidInCapitalPurchasesOfConvertibleNoteHedgesNetOfTax	70137000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	65688000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	110993000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2411000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	453023000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14846000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3928000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	113056000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	10575000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	595428000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16561000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4361000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1558000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	744858000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	126950000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	113056000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	110993000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18141000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6659000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7063000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16581000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	15708000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11848000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	16561000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	14846000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	11291000	USD
CY2020	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	4352000	USD
CY2019	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	301000	USD
CY2018	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2020	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	2889000	USD
CY2019	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	4034000	USD
CY2018	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1665000	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1900000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1454000	USD
CY2019	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2018	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2226000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1643000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	568000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5832000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4167000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	34607000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15751000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	35856000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10124000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	969000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9355000	USD
CY2020	supn	Increase Decrease In Prepaid Deferred Expense And Other Current Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets	10442000	USD
CY2019	supn	Increase Decrease In Prepaid Deferred Expense And Other Current Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets	2864000	USD
CY2018	supn	Increase Decrease In Prepaid Deferred Expense And Other Current Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets	2367000	USD
CY2020	supn	Increase Decrease In Accrued Product Returns And Rebates IncreaseDecreaseInAccruedProductReturnsAndRebates	10386000	USD
CY2019	supn	Increase Decrease In Accrued Product Returns And Rebates IncreaseDecreaseInAccruedProductReturnsAndRebates	566000	USD
CY2018	supn	Increase Decrease In Accrued Product Returns And Rebates IncreaseDecreaseInAccruedProductReturnsAndRebates	38720000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8272000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-11683000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4124000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	138399000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	143129000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	128986000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	378422000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	253170000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	79827000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	298541000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	95890000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	409707000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	491654000	USD
CY2020	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	15000000	USD
CY2019	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
CY2018	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3449000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2736000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	844000	USD
CY2020	us-gaap	Increase Decrease In Deferred Charges Investing IncreaseDecreaseInDeferredChargesInvesting	241000	USD
CY2019	us-gaap	Increase Decrease In Deferred Charges Investing IncreaseDecreaseInDeferredChargesInvesting	-1349000	USD
CY2018	us-gaap	Increase Decrease In Deferred Charges Investing IncreaseDecreaseInDeferredChargesInvesting	809000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34699000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-157924000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-413480000	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	402500000	USD
CY2020	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
CY2019	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
CY2018	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	10435000	USD
CY2020	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	65688000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4361000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3928000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11582000	USD
CY2020	supn	Purchases Of Convertible Note Hedge PurchasesOfConvertibleNoteHedge	802000	USD
CY2019	supn	Purchases Of Convertible Note Hedge PurchasesOfConvertibleNoteHedge	0	USD
CY2018	supn	Purchases Of Convertible Note Hedge PurchasesOfConvertibleNoteHedge	92897000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3559000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3928000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	376438000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	107259000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10867000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	91944000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	181381000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	192248000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100304000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	288640000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	181381000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	192248000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	2516000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	2516000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	1342000	USD
CY2020	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2019	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2018	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	15000000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	45428000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	51540000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	34772000	USD
CY2020	supn	Business Combination Contingent Consideration Arrangements Acquisition Liability BusinessCombinationContingentConsiderationArrangementsAcquisitionLiability	76700000	USD
CY2019	supn	Business Combination Contingent Consideration Arrangements Acquisition Liability BusinessCombinationContingentConsiderationArrangementsAcquisitionLiability	0	USD
CY2018	supn	Business Combination Contingent Consideration Arrangements Acquisition Liability BusinessCombinationContingentConsiderationArrangementsAcquisitionLiability	0	USD
CY2020	supn	Non Cash Capitalized Cost Of Intangible Assets NonCashCapitalizedCostOfIntangibleAssets	213000	USD
CY2019	supn	Non Cash Capitalized Cost Of Intangible Assets NonCashCapitalizedCostOfIntangibleAssets	1832000	USD
CY2018	supn	Non Cash Capitalized Cost Of Intangible Assets NonCashCapitalizedCostOfIntangibleAssets	250000	USD
CY2020	supn	Property And Equipment Additions From Utilization Of Tenant Improvement Allowance PropertyAndEquipmentAdditionsFromUtilizationOfTenantImprovementAllowance	0	USD
CY2019	supn	Property And Equipment Additions From Utilization Of Tenant Improvement Allowance PropertyAndEquipmentAdditionsFromUtilizationOfTenantImprovementAllowance	10151000	USD
CY2018	supn	Property And Equipment Additions From Utilization Of Tenant Improvement Allowance PropertyAndEquipmentAdditionsFromUtilizationOfTenantImprovementAllowance	0	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	Organization and Business<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supernus Pharmaceuticals, Inc. (the Company) was incorporated in Delaware and commenced operations in 2005. The Company is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel CNS product candidates including new potential treatments for attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s disease, epilepsy, depression, and rare CNS disorders. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has five commercial products: Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC. In addition, the Company has two late-stage development products included in its product candidates portfolio. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2020 USWM Acquisition and Navitor Development Agreements</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2020, the Company entered into a Development and Option Agreement (Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor). Under the terms of the Development Agreement, the Company and Navitor will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) in treatment-resistant depression (TRD). Refer to Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Unconsolidated VIEs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on the Navitor Development Agreement. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 28, 2020, the Company entered into a Sale and Purchase Agreement with US WorldMeds Partners, LLC to acquire the CNS portfolio of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). With the acquisition, completed on June 9, 2020, the Company added three established commercial products, APOKYN, XADAGO, and MYOBLOC, and a product candidate in late-stage development, SPN-830 (apomorphine infusion pump), to its portfolio. Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">USWM Acquisition</span>, for further discussion on the USWM Acquisition.
CY2020	supn	Number Of Proprietary Commercial Products NumberOfProprietaryCommercialProducts	5	product
CY2020	supn	Number Of Proprietary Development Products NumberOfProprietaryDevelopmentProducts	2	product
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on historical experience; various forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates on an ongoing basis. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the creditworthiness of customers entering into revenue arrangements, the valuation of the assets and liabilities acquired in the USWM Acquisition, and the fair values of our financial instruments, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.</span></div>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents, marketable securities, and accounts receivable. The counterparties are various corporations, governmental institutions, and financial institutions of high credit standing.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's cash, cash equivalents, and marketable securities are maintained in U.S. government agency debt and debt of well-known, investment grade corporations. Deposits held with banks may exceed the amount of governmental insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, and therefore, these bear minimal default risk</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregated Revenues</span>, for the concentration of net product sales.
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2020	supn	Sales Return Period Prior To Expiration SalesReturnPeriodPriorToExpiration	P6M
CY2020	supn	Sales Return Period SalesReturnPeriod	P12M
CY2020	supn	Sales Return Period SalesReturnPeriod	P12M
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2020	us-gaap	Advertising Expense AdvertisingExpense	54500000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	40800000	USD
CY2018	us-gaap	Advertising Expense AdvertisingExpense	43300000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	230000000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	230000000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	520397000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	392755000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	408897000	USD
CY2020	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	8500000	USD
CY2019	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	6900000	USD
CY2018	supn	Revenue From Royalty Agreement RevenueFromRoyaltyAgreement	5900000	USD
CY2020	supn	Contract With Customer Change In Refund Liability ContractWithCustomerChangeInRefundLiability	13800000	USD
CY2020	supn	Contract With Customer Change In Refund Liability ContractWithCustomerChangeInRefundLiability	13800000	USD
CY2019	supn	Contract With Customer Change In Refund Liability ContractWithCustomerChangeInRefundLiability	-400000	USD
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	80.9063
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	472306000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	747598000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11987000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10031000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	41000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	164000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	484252000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	757465000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	133893000	USD
CY2020Q4	supn	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year One To Year Two DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneToYearTwo	132480000	USD
CY2020Q4	supn	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year Two To Year Three DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearTwoToYearThree	129743000	USD
CY2020Q4	supn	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year Three To Year Four DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThreeToYearFour	88136000	USD
CY2020Q4	supn	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year Four DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearFour	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	484252000	USD
CY2020	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	115700000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	40900000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1900000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	76700000	USD
CY2020Q4	supn	Number Of Votes Per Common Share Held NumberOfVotesPerCommonShareHeld	1	segment
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16561000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14846000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11291000	USD
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	80.9063
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	80.9063
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	126950000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	113056000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	110993000	USD
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52615269	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52412181	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51989824	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1074474	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1404573	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2109048	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53689743	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53816754	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54098872	shares
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.41
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.16
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.13
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.36
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.10
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.05
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	29893000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	29333000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	26772000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11234000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	10930000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5621000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2200000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4551000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2450000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1629000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1281000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-760000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	41698000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34431000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29183000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	35417000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	30972000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	29437000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7281000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7543000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	3674000	USD
CY2020	supn	Effective Income Tax Rate Reconciliation Permanent Items Amount EffectiveIncomeTaxRateReconciliationPermanentItemsAmount	2654000	USD
CY2019	supn	Effective Income Tax Rate Reconciliation Permanent Items Amount EffectiveIncomeTaxRateReconciliationPermanentItemsAmount	1332000	USD
CY2018	supn	Effective Income Tax Rate Reconciliation Permanent Items Amount EffectiveIncomeTaxRateReconciliationPermanentItemsAmount	-2196000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3602000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	2071000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3199000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	348000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-2992000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	716000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-400000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-353000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	751000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	41698000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34431000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29183000	USD
CY2020Q4	supn	Deferred Tax Assets Convertible Bond Hedge DeferredTaxAssetsConvertibleBondHedge	12420000	USD
CY2019Q4	supn	Deferred Tax Assets Convertible Bond Hedge DeferredTaxAssetsConvertibleBondHedge	17197000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	17529000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	15123000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	13547000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	10349000	USD
CY2020Q4	supn	Deferred Tax Assets Royalty Revenue DeferredTaxAssetsRoyaltyRevenue	3777000	USD
CY2019Q4	supn	Deferred Tax Assets Royalty Revenue DeferredTaxAssetsRoyaltyRevenue	5320000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3151000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3817000	USD
CY2020Q4	supn	Deferred Tax Asset Amortization DeferredTaxAssetAmortization	0	USD
CY2019Q4	supn	Deferred Tax Asset Amortization DeferredTaxAssetAmortization	4617000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13164000	USD
CY2019Q4	supn	Deferred Tax Liabilities Infringement Legal Cost DeferredTaxLiabilitiesInfringementLegalCost	10613000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2245000	USD
CY2020Q4	supn	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	14542000	USD
CY2019Q4	supn	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	8187000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5303000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2510000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	83433000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	69365000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	582000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	82851000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	69354000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	79545000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0	USD
CY2020Q4	supn	Deferred Tax Liabilities Debt Discount On Convertible Notes DeferredTaxLiabilitiesDebtDiscountOnConvertibleNotes	10190000	USD
CY2019Q4	supn	Deferred Tax Liabilities Debt Discount On Convertible Notes DeferredTaxLiabilitiesDebtDiscountOnConvertibleNotes	14109000	USD
CY2020Q4	supn	Deferred Tax Liabilities Infringement Legal Cost DeferredTaxLiabilitiesInfringementLegalCost	10897000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	10674000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	5237000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3458000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2778000	USD
CY2020Q4	supn	Deferred Tax Liabilities481a Adjustment DeferredTaxLiabilities481aAdjustment	315000	USD
CY2019Q4	supn	Deferred Tax Liabilities481a Adjustment DeferredTaxLiabilities481aAdjustment	2126000	USD
CY2020Q4	supn	Deferred Tax Liabilities Unrealized Gain On Marketable Securities DeferredTaxLiabilitiesUnrealizedGainOnMarketableSecurities	2987000	USD
CY2019Q4	supn	Deferred Tax Liabilities Unrealized Gain On Marketable Securities DeferredTaxLiabilitiesUnrealizedGainOnMarketableSecurities	2428000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	118066000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	37291000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	35215000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	32063000	USD
CY2020Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	600000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	600000	USD
CY2020Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	3500000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	3029000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	635000	USD
CY2018	supn	Income Tax Expense On Uncertain Tax Position Alternate Minimum Tax IncomeTaxExpenseOnUncertainTaxPositionAlternateMinimumTax	600000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5881000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5978000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8848000	USD
CY2020	supn	Income Tax Expense On Uncertain Tax Position Alternate Minimum Tax IncomeTaxExpenseOnUncertainTaxPositionAlternateMinimumTax	600000	USD
CY2019	supn	Income Tax Expense On Uncertain Tax Position Alternate Minimum Tax IncomeTaxExpenseOnUncertainTaxPositionAlternateMinimumTax	3000000.0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5978000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8848000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8859000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1027000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	208000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1108000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	221000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	49000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	484000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1345000	USD
CY2020	supn	Income Tax Expense On Uncertain Tax Position IncomeTaxExpenseOnUncertainTaxPosition	300000	USD
CY2019	supn	Income Tax Expense On Uncertain Tax Position IncomeTaxExpenseOnUncertainTaxPosition	200000	USD
CY2018	supn	Income Tax Expense On Uncertain Tax Position IncomeTaxExpenseOnUncertainTaxPosition	300000	USD
CY2020	supn	Unrecognized Tax Benefits Increase Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsIncreaseResultingFromLapseOfApplicableStatuteOfLimitations	200000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20231000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21279000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	20874000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0	USD
CY2020Q4	supn	Lease Right Of Use Asset LeaseRightOfUseAsset	41105000	USD
CY2019Q4	supn	Lease Right Of Use Asset LeaseRightOfUseAsset	21279000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	6877000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3760000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2825000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3761000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28579000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30440000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20235000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2020Q4	supn	Lease Liability LeaseLiability	56335000	USD
CY2019Q4	supn	Lease Liability LeaseLiability	33265000	USD
CY2020	supn	Operating Lease Fixed Lease Cost OperatingLeaseFixedLeaseCost	5333000	USD
CY2019	supn	Operating Lease Fixed Lease Cost OperatingLeaseFixedLeaseCost	4990000	USD
CY2020	supn	Operating Lease Variable Lease Cost OperatingLeaseVariableLeaseCost	2145000	USD
CY2019	supn	Operating Lease Variable Lease Cost OperatingLeaseVariableLeaseCost	1887000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	7478000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1873000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	333000	USD
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	USD
CY2020	supn	Financing Lease Cost FinancingLeaseCost	2206000	USD
CY2019	supn	Financing Lease Cost FinancingLeaseCost	0	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	6949000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	5337000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	802000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2478000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	35594000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	22747000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y8M12D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0433
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0247
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2638000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	3665000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5066000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3946000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4474000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	3665000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2701000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	3665000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2587000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	3665000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	24145000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	7329000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	41611000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	25935000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9272000	USD
CY2020Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1939000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	32339000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	23996000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	34237000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	18535000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	364342000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24840000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15700000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5200000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5200000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	24200000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	24200000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	21400000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	21400000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	21400000	USD
CY2020Q4	supn	Allowance For Expected Sales Deductions AllowanceForExpectedSalesDeductions	11400000	USD
CY2019Q4	supn	Allowance For Expected Sales Deductions AllowanceForExpectedSalesDeductions	11000000.0	USD
CY2020Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	22208000	USD
CY2019Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	4582000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8985000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11428000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	17132000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10618000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	48325000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	26628000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	22747000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	0	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	54864000	USD
CY2019Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	29767000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	17040000	USD
CY2019Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	12699000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	37824000	USD
CY2019Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	17068000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4300000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1500000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1900000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16008000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11223000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	13890000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	0	USD
CY2020Q4	supn	Accrued Clinical Trial And Clinical Supply Costs Current AccruedClinicalTrialAndClinicalSupplyCostsCurrent	12842000	USD
CY2019Q4	supn	Accrued Clinical Trial And Clinical Supply Costs Current AccruedClinicalTrialAndClinicalSupplyCostsCurrent	13285000	USD
CY2020Q4	us-gaap	Inventory Adjustments InventoryAdjustments	9587000	USD
CY2019Q4	us-gaap	Inventory Adjustments InventoryAdjustments	1095000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7730000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3936000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6147000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10141000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3760000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2825000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	USD
CY2019Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	2443000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8970000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4766000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	78934000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49714000	USD
CY2020Q4	supn	Accrued Rebates AccruedRebates	96589000	USD
CY2019Q4	supn	Accrued Rebates AccruedRebates	88811000	USD
CY2020Q4	supn	Accrued Product Returns AccruedProductReturns	29603000	USD
CY2019Q4	supn	Accrued Product Returns AccruedProductReturns	18818000	USD
CY2020Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	126192000	USD
CY2019Q4	supn	Accrued Product Returns And Rebates AccruedProductReturnsAndRebates	107629000	USD
CY2020Q4	supn	Non Recourse Liability Noncurrent NonRecourseLiabilityNoncurrent	13410000	USD
CY2019Q4	supn	Non Recourse Liability Noncurrent NonRecourseLiabilityNoncurrent	19248000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20235000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	9146000	USD
CY2019Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	9409000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	42791000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28657000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5050000	USD
CY2020	us-gaap	Interest Income Other InterestIncomeOther	18704000	USD
CY2019	us-gaap	Interest Income Other InterestIncomeOther	21623000	USD
CY2018	us-gaap	Interest Income Other InterestIncomeOther	13843000	USD
CY2020	us-gaap	Interest Expense InterestExpense	19435000	USD
CY2019	us-gaap	Interest Expense InterestExpense	18207000	USD
CY2018	us-gaap	Interest Expense InterestExpense	13840000	USD
CY2020	us-gaap	Interest Expense Other InterestExpenseOther	4319000	USD
CY2019	us-gaap	Interest Expense Other InterestExpenseOther	4500000	USD
CY2018	us-gaap	Interest Expense Other InterestExpenseOther	4271000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1084000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4268000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16600000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	15700000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11800000	USD
CY2020	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	16000000.0	USD
CY2019	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	21300000	USD
CY2018	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	13800000	USD
CY2020	supn	Defined Contribution Plan Eligibility Minimum Age DefinedContributionPlanEligibilityMinimumAge	P18Y
CY2020	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.90
CY2020	supn	Defined Contribution Plan Employer Match Level One DefinedContributionPlanEmployerMatchLevelOne	1
CY2020	supn	Defined Contribution Plan Employer Match Employee Contribution Level One DefinedContributionPlanEmployerMatchEmployeeContributionLevelOne	0.03
CY2020	supn	Defined Contribution Plan Employer Match Level Two DefinedContributionPlanEmployerMatchLevelTwo	0.50
CY2020	supn	Employer Match Employee Contribution Level Two EmployerMatchEmployeeContributionLevelTwo	0.02
CY2020	supn	Defined Contribution Plan Maximum Discretionary Employer Contribution Percentage DefinedContributionPlanMaximumDiscretionaryEmployerContributionPercentage	0.60
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2600000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2300000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2100000	USD
CY2014Q3	supn	Non Recourse Debt Sale Of Future Royalties Noncurrent NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent	30000000.0	USD

Files In Submission

Name	View Source	Status
0001356576-21-000028-index-headers.html	Edgar Link	pending
0001356576-21-000028-index.html	Edgar Link	pending
0001356576-21-000028.txt	Edgar Link	pending
0001356576-21-000028-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
supn-20201231.htm	Edgar Link	pending
supn-20201231.xsd	Edgar Link	pending
supn-20201231xex1010.htm	Edgar Link	pending
supn-20201231xex1011.htm	Edgar Link	pending
supn-20201231xex1012.htm	Edgar Link	pending
supn-20201231xex109.htm	Edgar Link	pending
supn-20201231xex21.htm	Edgar Link	pending
supn-20201231xex231.htm	Edgar Link	pending
supn-20201231xex311.htm	Edgar Link	pending
supn-20201231xex312.htm	Edgar Link	pending
supn-20201231xex321.htm	Edgar Link	pending
supn-20201231xex322.htm	Edgar Link	pending
supn-20201231_cal.xml	Edgar Link	unprocessable
supn-20201231_def.xml	Edgar Link	unprocessable
supn-20201231_g1.jpg	Edgar Link	pending
supn-20201231_g2.jpg	Edgar Link	pending
supn-20201231_htm.xml	Edgar Link	completed
supn-20201231_lab.xml	Edgar Link	unprocessable
supn-20201231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SUPN
SUPERNUS PHARMACEUTICALS, INC. Stock $supn

2020 Form 10-K Financial Statement

#000135657621000028 Filed on March 08, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUPN SUPERNUS PHARMACEUTICALS, INC. Stock $supn

2020 Form 10-K Financial Statement

#000135657621000028 Filed on March 08, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUPN
SUPERNUS PHARMACEUTICALS, INC. Stock $supn